Treace(US:TMCI) ZACKSยท2025-02-28 00:25Company Performance - Treace Medical Concepts reported a quarterly loss of $0.01 per share, better than the Zacks Consensus Estimate of a loss of $0.03, and an improvement from a loss of $0.10 per share a year ago, representing an earnings surprise of 66.67% [1] - The company posted revenues of $68.71 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.16% and showing an increase from $62.21 million in the same quarter last year [2] - Over the last four quarters, Treace Medical Concepts has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Movement and Outlook - Treace Medical Concepts shares have increased approximately 30.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.3% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.25 for the coming quarter and -$0.77 for the current fiscal year [4][7] - The estimate revisions trend for Treace Medical Concepts is currently mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Treace Medical Concepts belongs, is currently ranked in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]